By Healio/Endocrine Today
Sandoz on Wednesday announced an agreement with Gan & Lee Pharmaceuticals to commercialize biosimilar versions of insulins used to treat patients with type 1 and type 2 diabetes, according to an industry press release.
The agreement covers biosimilar insulins in early and clinical development for the European Union and the United States for the top three selling branded insulins by sales: glargine (Lantus, Sanofi), lispro (Humalog, Eli Lilly) and aspart (NovoLog, Novo Nordisk). Sandoz, which currently has eight marketed biosimilars, is a division of Novartis Group.
Gan & Lee is a leading insulin supplier headquartered in China with more than 20 years’ experience in insulins and production capacity, according to Sandoz. Under the terms of the agreement, Sandoz will be fully responsible for commercializing these medicines in the EU, U.S., Switzerland, Japan, South Korea, Canada, Australia and New Zealand. Gan & Lee will be responsible for manufacturing and development, with support from Sandoz, and shall adhere to the stringent manufacturing requirements established for Sandoz biosimilars. Other specific terms of the agreement are confidential.